EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6

Ensembl ID : ENSUMAG00000011258
Gene Symbol: CACNG6
3 Cross references
248 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSUMAG00000011263
Gene Symbol: CACNG7
4 Cross references
253 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSUMAG00000004898
Gene Symbol: CACNA1A
4 Cross references
283 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSUMAG00000020120
Gene Symbol: CACNA1D
4 Cross references
281 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSUMAG00000016658
Gene Symbol: CACNA1E
4 Cross references
294 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSUMAG00000006984
Gene Symbol: CACNA1F
4 Cross references
178 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSUMAG00000001163
Gene Symbol: CACNA1S
4 Cross references
259 Possible Orthologues:

Carbonic Anhydrase 1

Ensembl ID : ENSUMAG00000015131
Gene Symbol: CA1
4 Cross references
285 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSUMAG00000013569
Gene Symbol: CA12
4 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 13

Ensembl ID : ENSUMAG00000015126
Gene Symbol: CA13
4 Cross references
288 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSUMAG00000003751
Gene Symbol: CA14
4 Cross references
210 Possible Orthologues:

Carbonic Anhydrase 2

Ensembl ID : ENSUMAG00000015145
Gene Symbol: CA2
4 Cross references
282 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).